Cosmos Holdings (COSM) AI Stock Analysis

• Market Cap: $20.93M
• Dividend Yield: N/A
• Average Volume (3M): 1.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.10
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.53
• Shares Outstanding: 31,013,876
• 10 Day Avg. Volume: 1,246,475
• 30 Day Avg. Volume: 1,183,471
• PEG Ratio: 0.02
• Price to Book (P/B): 0.52
• Price to Sales (P/S): 0.24
• P/FCF Ratio: -1.57
• Enterprise Value/Market Cap: 1.29
• Enterprise Value/Revenue: 0.45
• Enterprise Value/Gross Profit: 3.96
• Enterprise Value/Ebitda: -1.81
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $0.53 ▼(-4.00% Downside)

Cosmos Holdings faces significant financial and technical challenges. The company's financial performance is weak, with profitability and cash flow under pressure. Technical analysis indicates a bearish trend, and the valuation metrics are unattractive due to negative earnings. These factors collectively result in a low overall stock score.

Positive Factors

Revenue Growth

The 8.53% revenue growth indicates a positive trend in market demand and the company's ability to expand its market reach, which is crucial for long-term sustainability.

Distribution Network

A strong distribution network enhances the company's ability to efficiently deliver products, supporting market penetration and competitive positioning over time.

Product Partnerships

Strategic partnerships allow access to a broader range of products and markets, reinforcing the company's competitive edge and potential for revenue diversification.

Negative Factors

Profitability Challenges

Negative profit margins indicate operational inefficiencies and cost management issues, which could hinder long-term financial health if not addressed.

Cash Flow Issues

Negative cash flow suggests liquidity constraints, limiting the company's ability to invest in growth opportunities and manage debt obligations effectively.

Return on Equity

Negative return on equity reflects poor financial performance, potentially affecting investor confidence and the company's ability to raise capital.

Cosmos Holdings Business Overview & Revenue Model

Company Description

Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece and the United Kingdom; and operates a warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.

How the Company Makes Money

Cosmos Holdings generates revenue through multiple streams, including the wholesale distribution of pharmaceuticals, which involves sourcing products from manufacturers and selling them to pharmacies, hospitals, and clinics. The company also profits from its retail operations, which include direct sales of over-the-counter medications and dietary supplements to consumers. Additionally, Cosmos Holdings engages in partnerships with international manufacturers, allowing it to expand its product offerings and leverage marketing opportunities. These partnerships enhance its revenue potential by providing access to a broader range of products and markets, thus contributing to its overall earnings.

Cosmos Holdings Financial Statement Overview

Summary

Cosmos Holdings is facing significant financial challenges across all verticals. While there is some revenue growth, profitability and cash flow remain under pressure. The balance sheet shows moderate leverage but lacks strong equity returns. Overall, the company needs to address its operational inefficiencies and improve cash flow management to enhance financial health.

Income Statement

Cosmos Holdings has shown some improvement in revenue growth with an 8.53% increase in the TTM period. However, profitability remains a concern with negative net profit margins and EBIT margins, indicating ongoing operational challenges. The gross profit margin has slightly improved but remains low, reflecting pressure on cost management.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.58, suggesting manageable leverage. However, the return on equity is negative, indicating that the company is not generating sufficient returns on shareholders' equity. The equity ratio is also low, highlighting potential risks in financial stability.

Cash Flow

Cosmos Holdings' cash flow situation is concerning, with negative operating cash flow and free cash flow. Although there is a positive free cash flow growth rate, the operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is positive, suggesting some efficiency in converting earnings to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	59.79M	54.43M	53.38M	50.35M	56.24M	55.41M
Gross Profit	6.82M	4.31M	4.35M	5.96M	8.33M	8.06M
EBITDA	-14.92M	-13.92M	-17.06M	-8.90M	-3.82M	4.39M
Net Income	-18.54M	-16.18M	-18.54M	-13.83M	-7.96M	820.79K
Balance Sheet
Total Assets	69.49M	54.31M	66.01M	68.04M	49.43M	43.84M
Cash, Cash Equivalents and Short-Term Investments	922.62K	336.25K	3.85M	20.76M	297.95K	851.19K
Total Debt	21.07M	11.82M	12.42M	12.03M	27.12M	32.04M
Total Liabilities	46.36M	29.78M	29.97M	28.38M	45.05M	48.01M
Stockholders Equity	23.13M	24.53M	36.04M	39.66M	4.38M	-4.16M
Cash Flow
Free Cash Flow	-10.27M	-8.14M	-24.80M	-15.25M	-7.99M	-11.62M
Operating Cash Flow	-9.20M	-7.72M	-15.64M	-14.87M	-7.10M	-11.50M
Investing Cash Flow	-1.95M	-798.27K	-13.76M	-21.50K	-826.82K	-117.74K
Financing Cash Flow	12.49M	5.05M	12.69M	35.05M	7.27M	12.46M

Cosmos Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COSM, the sentiment is Negative. The current price of 0.55 is below the 20-day moving average (MA) of 0.67, below the 50-day MA of 0.89, and below the 200-day MA of 0.64, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 29.03 is Positive, neither overbought nor oversold. The STOCH value of 12.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COSM.

Cosmos Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AYTU	48 Neutral	$21.11M	-0.76	-50.23%	―	-15.61%	-68.96%
TXMD	47 Neutral	$13.54M	-29.32	0.27%	―	75.19%	―
SCYX	46 Neutral	$26.45M	-1.11	-53.29%	―	-65.77%	38.61%
PRPH	41 Neutral	$6.51M	―	―	―	―	―
RMTI	41 Neutral	$36.84M	―	-16.67%	―	-23.60%	-179.33%
COSM	38 Underperform	$20.93M	-0.68	-63.82%	―	―	―

Cosmos Holdings Corporate Events

Cosmos Holdings Appoints Theodoros Karkantzos to Board

On September 30, 2025, Cosmos Health Inc. appointed Theodoros C. Karkantzos as a member of its Board of Directors and the Nominating and Corporate Governance Committee. Mr. Karkantzos, who has over 15 years of experience in investment and business development, was elected at the annual general meeting of stockholders. His expertise includes finance, strategy, private equity, and asset management, and he holds distinguished academic qualifications from the University of Cambridge and the University of Warwick. The appointment is expected to enhance the company’s strategic direction, leveraging Mr. Karkantzos’s extensive experience in various sectors, including real estate and healthcare.

The most recent analyst rating on (COSM) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cosmos Holdings stock, see the COSM Stock Forecast page.

Cosmos Holdings Approves Share Increase at Annual Meeting

At the 2025 Annual Meeting of Stockholders held on September 30, 2025, Cosmos Holdings‘ stockholders approved an amendment to the company’s Articles of Incorporation, increasing the number of authorized shares to 1.5 billion shares of common stock and 300 million shares of preferred stock. This decision, along with the election of directors and approval of various proposals, signifies a strategic move to enhance the company’s capital structure and governance, potentially impacting its market operations and shareholder value.

The most recent analyst rating on (COSM) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cosmos Holdings stock, see the COSM Stock Forecast page.